PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.65%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
44.07%
G&A growth while RVPH reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
473.10%
Other expenses change of 473.10% while RVPH maintains costs. Bruce Berkowitz would investigate efficiency.
6.92%
Operating expenses growth while RVPH reduces costs. John Neff would investigate differences.
6.92%
Total costs growth while RVPH reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
473.10%
D&A change of 473.10% while RVPH maintains D&A. Bruce Berkowitz would investigate efficiency.
73.55%
EBITDA growth exceeding 1.5x RVPH's 5.85%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-6.92%
Operating income decline while RVPH shows 7.11% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
163.21%
Other expenses growth while RVPH reduces costs. John Neff would investigate differences.
121.05%
Pre-tax income growth exceeding 1.5x RVPH's 5.94%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.05%
Net income growth exceeding 1.5x RVPH's 5.90%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
121.15%
EPS growth exceeding 1.5x RVPH's 7.69%. David Dodd would verify competitive advantages.
115.11%
Diluted EPS growth exceeding 1.5x RVPH's 7.69%. David Dodd would verify competitive advantages.
2.25%
Share count reduction below 50% of RVPH's 2.47%. Michael Burry would check for concerns.
42.15%
Diluted share reduction below 50% of RVPH's 2.47%. Michael Burry would check for concerns.